Ecraid
@ecraid.bsky.social
The European Clinical Research Alliance for Infectious Diseases is a not-for profit foundation that advances clinical research in infectious diseases.
🤧 The EU-funded #ECRAIDPrime trial has randomised its first 3 remote patients in the #UK this flu season — launching a patient-centric approach to expand access and community participation. This is a big step for infectious disease trials in #PrimaryCare and #Europe. 🎉 Congrats to the Oxford team!
January 12, 2026 at 2:25 PM
🤧 The EU-funded #ECRAIDPrime trial has randomised its first 3 remote patients in the #UK this flu season — launching a patient-centric approach to expand access and community participation. This is a big step for infectious disease trials in #PrimaryCare and #Europe. 🎉 Congrats to the Oxford team!
🎧Recording available!
Tune into this webinar in collaboration with @europeanrespsoc.bsky.social on #PandemicPreparedness 👇
channel.ersnet.org/media-114951...
Tune into this webinar in collaboration with @europeanrespsoc.bsky.social on #PandemicPreparedness 👇
channel.ersnet.org/media-114951...
December 29, 2025 at 11:19 AM
🎧Recording available!
Tune into this webinar in collaboration with @europeanrespsoc.bsky.social on #PandemicPreparedness 👇
channel.ersnet.org/media-114951...
Tune into this webinar in collaboration with @europeanrespsoc.bsky.social on #PandemicPreparedness 👇
channel.ersnet.org/media-114951...
As we close out 2025, we look back on a truly landmark year for Ecraid: one defined by growth, collaboration, and impact. Thank you to our partners, collaborators, sites, investigators, and team members for your commitment and trust.
Happy holidays, and all the best for the year ahead 🌟
Happy holidays, and all the best for the year ahead 🌟
December 24, 2025 at 9:02 AM
As we close out 2025, we look back on a truly landmark year for Ecraid: one defined by growth, collaboration, and impact. Thank you to our partners, collaborators, sites, investigators, and team members for your commitment and trust.
Happy holidays, and all the best for the year ahead 🌟
Happy holidays, and all the best for the year ahead 🌟
🎉 Amazing milestones reached in three of our perpetual observational studies (POS)! We are tremendously proud of ALL the site teams behind these studies, for making it happen as 2025 comes to an end - a great way to wrap up the year!
Thank you!
ecraid.eu/ecraid-base/...
Thank you!
ecraid.eu/ecraid-base/...
December 23, 2025 at 9:30 AM
🎉 Amazing milestones reached in three of our perpetual observational studies (POS)! We are tremendously proud of ALL the site teams behind these studies, for making it happen as 2025 comes to an end - a great way to wrap up the year!
Thank you!
ecraid.eu/ecraid-base/...
Thank you!
ecraid.eu/ecraid-base/...
Announcing Module 2 of the Ecraid x @ESCMID online course on Biomedical Data & Sample Governance: 'How to design your data governance framework' in collaboration with CoMeCT, IDDO, CERCLE, @who.int and @tghn-news.bsky.social
🎧👉 www.escmid.org/education/ed...
#DataGovernance #EpidemicPreparedness
🎧👉 www.escmid.org/education/ed...
#DataGovernance #EpidemicPreparedness
December 22, 2025 at 12:28 PM
Announcing Module 2 of the Ecraid x @ESCMID online course on Biomedical Data & Sample Governance: 'How to design your data governance framework' in collaboration with CoMeCT, IDDO, CERCLE, @who.int and @tghn-news.bsky.social
🎧👉 www.escmid.org/education/ed...
#DataGovernance #EpidemicPreparedness
🎧👉 www.escmid.org/education/ed...
#DataGovernance #EpidemicPreparedness
📩Our final newsletter of 2025 is out!
As we close 2025, we also say farewell to our CEO, @marcbonten.bsky.social. We are proud of what we have achieved together over the years & look ahead with confidence to 2026, welcoming @lenniederde.bsky.social onboard!
Read more & subscribe: bit.ly/Dec25Ecraid
As we close 2025, we also say farewell to our CEO, @marcbonten.bsky.social. We are proud of what we have achieved together over the years & look ahead with confidence to 2026, welcoming @lenniederde.bsky.social onboard!
Read more & subscribe: bit.ly/Dec25Ecraid
December 18, 2025 at 1:18 PM
📩Our final newsletter of 2025 is out!
As we close 2025, we also say farewell to our CEO, @marcbonten.bsky.social. We are proud of what we have achieved together over the years & look ahead with confidence to 2026, welcoming @lenniederde.bsky.social onboard!
Read more & subscribe: bit.ly/Dec25Ecraid
As we close 2025, we also say farewell to our CEO, @marcbonten.bsky.social. We are proud of what we have achieved together over the years & look ahead with confidence to 2026, welcoming @lenniederde.bsky.social onboard!
Read more & subscribe: bit.ly/Dec25Ecraid
The rationale & design of the #PNEUMO study Europe was recently published!
👉 bit.ly/3MBR6d4
Now in its final year, the studies primary goal is to estimate the incidence of pneumococcal #pneumonia & serotype prevalence among adults in Europe.
#ClinicalTrials #InfectiousDiseases #ResearchSky #IDSky
👉 bit.ly/3MBR6d4
Now in its final year, the studies primary goal is to estimate the incidence of pneumococcal #pneumonia & serotype prevalence among adults in Europe.
#ClinicalTrials #InfectiousDiseases #ResearchSky #IDSky
December 16, 2025 at 8:16 AM
The rationale & design of the #PNEUMO study Europe was recently published!
👉 bit.ly/3MBR6d4
Now in its final year, the studies primary goal is to estimate the incidence of pneumococcal #pneumonia & serotype prevalence among adults in Europe.
#ClinicalTrials #InfectiousDiseases #ResearchSky #IDSky
👉 bit.ly/3MBR6d4
Now in its final year, the studies primary goal is to estimate the incidence of pneumococcal #pneumonia & serotype prevalence among adults in Europe.
#ClinicalTrials #InfectiousDiseases #ResearchSky #IDSky
Trainings, talent & top science: the last Ecraid Learning Newsletter of the year is out!
Filled to the brim with exciting courses, testimonials from participants at past ones, freshly-published science and interesting interviews & blogs!
👉🏽https://bit.ly/LearningDecEcraid
Filled to the brim with exciting courses, testimonials from participants at past ones, freshly-published science and interesting interviews & blogs!
👉🏽https://bit.ly/LearningDecEcraid
December 15, 2025 at 9:48 AM
Trainings, talent & top science: the last Ecraid Learning Newsletter of the year is out!
Filled to the brim with exciting courses, testimonials from participants at past ones, freshly-published science and interesting interviews & blogs!
👉🏽https://bit.ly/LearningDecEcraid
Filled to the brim with exciting courses, testimonials from participants at past ones, freshly-published science and interesting interviews & blogs!
👉🏽https://bit.ly/LearningDecEcraid
Ecraid joins the #PrIMAVeRa_AMR Consortium to accelerate #AMR modelling!
This strategic partnership is a powerful step forward in the fight against #AntimicrobialResistance.
👉🏽Learn more about this vital collaboration & its impact on public health: www.ecraid.eu/news/ecraid-...
#StopSuperbugs
This strategic partnership is a powerful step forward in the fight against #AntimicrobialResistance.
👉🏽Learn more about this vital collaboration & its impact on public health: www.ecraid.eu/news/ecraid-...
#StopSuperbugs
December 10, 2025 at 1:33 PM
Ecraid joins the #PrIMAVeRa_AMR Consortium to accelerate #AMR modelling!
This strategic partnership is a powerful step forward in the fight against #AntimicrobialResistance.
👉🏽Learn more about this vital collaboration & its impact on public health: www.ecraid.eu/news/ecraid-...
#StopSuperbugs
This strategic partnership is a powerful step forward in the fight against #AntimicrobialResistance.
👉🏽Learn more about this vital collaboration & its impact on public health: www.ecraid.eu/news/ecraid-...
#StopSuperbugs
Ventilator-associated pneumonia can be a challenge to study in traditional randomised controlled trials due to low patient and event numbers. This recent paper explores whether adaptive trial designs can make VAP prevention trials more efficient
link.springer.com/article/10.1...
link.springer.com/article/10.1...
December 4, 2025 at 1:03 PM
Ventilator-associated pneumonia can be a challenge to study in traditional randomised controlled trials due to low patient and event numbers. This recent paper explores whether adaptive trial designs can make VAP prevention trials more efficient
link.springer.com/article/10.1...
link.springer.com/article/10.1...
📩 Our latest newsletter is out! We’re thrilled to welcome our new CEO, @lenniederde.bsky.social, marking a fresh chapter in Ecraid’s journey. Other updates in this edition:
✅ ECRAID-Base: new publications
✅ ECRAID-Prime: launch of third treatment arm
And more…
📫 Subscribe now: bit.ly/NovEcraid
✅ ECRAID-Base: new publications
✅ ECRAID-Prime: launch of third treatment arm
And more…
📫 Subscribe now: bit.ly/NovEcraid
November 13, 2025 at 1:31 PM
📩 Our latest newsletter is out! We’re thrilled to welcome our new CEO, @lenniederde.bsky.social, marking a fresh chapter in Ecraid’s journey. Other updates in this edition:
✅ ECRAID-Base: new publications
✅ ECRAID-Prime: launch of third treatment arm
And more…
📫 Subscribe now: bit.ly/NovEcraid
✅ ECRAID-Base: new publications
✅ ECRAID-Prime: launch of third treatment arm
And more…
📫 Subscribe now: bit.ly/NovEcraid
We are very pleased to announce Lennie Derde as Ecraid's new Chief Executive Officer effective 1 January 2026. She will succeed Ecraid’s co-founder @marcbonten.bsky.social
Read more 👉 ecraid.eu/articles/len...
@umcutrecht.bsky.social @ec.europa.eu @horizoneu.bsky.social
Read more 👉 ecraid.eu/articles/len...
@umcutrecht.bsky.social @ec.europa.eu @horizoneu.bsky.social
November 12, 2025 at 1:43 PM
We are very pleased to announce Lennie Derde as Ecraid's new Chief Executive Officer effective 1 January 2026. She will succeed Ecraid’s co-founder @marcbonten.bsky.social
Read more 👉 ecraid.eu/articles/len...
@umcutrecht.bsky.social @ec.europa.eu @horizoneu.bsky.social
Read more 👉 ecraid.eu/articles/len...
@umcutrecht.bsky.social @ec.europa.eu @horizoneu.bsky.social
🚨 1 in 6 bacterial infections is now antibiotic-resistant. The new WHO GLASS Report demands immediate action.
Ecraid is Europe's answer. We're bridging the crisis-to-solution gap.
👉🏽Read how: bit.ly/WHOGLASS
Ecraid is Europe's answer. We're bridging the crisis-to-solution gap.
👉🏽Read how: bit.ly/WHOGLASS
November 3, 2025 at 1:32 PM
🚨 1 in 6 bacterial infections is now antibiotic-resistant. The new WHO GLASS Report demands immediate action.
Ecraid is Europe's answer. We're bridging the crisis-to-solution gap.
👉🏽Read how: bit.ly/WHOGLASS
Ecraid is Europe's answer. We're bridging the crisis-to-solution gap.
👉🏽Read how: bit.ly/WHOGLASS
🦠 New tool to track #antibioticresistance: the Emerging Resistance Index (ERI).
💡Using data from 38 surveillance systems across Europe, researchers found rapid resistance emerging to all new Gram-negative antibiotics.
The ERI could help guide surveillance & policy!
👉Read the article bit.ly/4hgk51g
💡Using data from 38 surveillance systems across Europe, researchers found rapid resistance emerging to all new Gram-negative antibiotics.
The ERI could help guide surveillance & policy!
👉Read the article bit.ly/4hgk51g
October 20, 2025 at 7:24 AM
🦠 New tool to track #antibioticresistance: the Emerging Resistance Index (ERI).
💡Using data from 38 surveillance systems across Europe, researchers found rapid resistance emerging to all new Gram-negative antibiotics.
The ERI could help guide surveillance & policy!
👉Read the article bit.ly/4hgk51g
💡Using data from 38 surveillance systems across Europe, researchers found rapid resistance emerging to all new Gram-negative antibiotics.
The ERI could help guide surveillance & policy!
👉Read the article bit.ly/4hgk51g
Meet Eveline Verheijen, our new Site Management Organisation (SMO) Manager!
🔬 Eveline leads our vaccination site in Utrecht - one of the top-performing study sites in NL. Her focus on collaboration, quality & efficiency helps accelerate clinical research.
🔎Read the full interview: bit.ly/SMO-Eveline
🔬 Eveline leads our vaccination site in Utrecht - one of the top-performing study sites in NL. Her focus on collaboration, quality & efficiency helps accelerate clinical research.
🔎Read the full interview: bit.ly/SMO-Eveline
October 17, 2025 at 12:14 PM
Meet Eveline Verheijen, our new Site Management Organisation (SMO) Manager!
🔬 Eveline leads our vaccination site in Utrecht - one of the top-performing study sites in NL. Her focus on collaboration, quality & efficiency helps accelerate clinical research.
🔎Read the full interview: bit.ly/SMO-Eveline
🔬 Eveline leads our vaccination site in Utrecht - one of the top-performing study sites in NL. Her focus on collaboration, quality & efficiency helps accelerate clinical research.
🔎Read the full interview: bit.ly/SMO-Eveline
📩 Our latest newsletter is out!
Discover significant developments at Ecraid, including the launch of our new campaign to foster strategic collaborations, #PartnerForImpact!
📫 Stay informed, subscribe now bit.ly/43kBWhJ
#PartnerWithEcraid #ClinicalResearch #InfectiousDiseases #Education #Knowledge
Discover significant developments at Ecraid, including the launch of our new campaign to foster strategic collaborations, #PartnerForImpact!
📫 Stay informed, subscribe now bit.ly/43kBWhJ
#PartnerWithEcraid #ClinicalResearch #InfectiousDiseases #Education #Knowledge
October 14, 2025 at 10:54 AM
📩 Our latest newsletter is out!
Discover significant developments at Ecraid, including the launch of our new campaign to foster strategic collaborations, #PartnerForImpact!
📫 Stay informed, subscribe now bit.ly/43kBWhJ
#PartnerWithEcraid #ClinicalResearch #InfectiousDiseases #Education #Knowledge
Discover significant developments at Ecraid, including the launch of our new campaign to foster strategic collaborations, #PartnerForImpact!
📫 Stay informed, subscribe now bit.ly/43kBWhJ
#PartnerWithEcraid #ClinicalResearch #InfectiousDiseases #Education #Knowledge
@marcbonten.bsky.social has dedicated his career to advancing #clinicalmicrobiology & combatting #antimicrobialresistance. In his new role as Vice-Dean Education at @umcutrecht.bsky.social
he continues to inspire the next generation of healthcare scientists & researchers: ecraid.eu/articles/edu...
he continues to inspire the next generation of healthcare scientists & researchers: ecraid.eu/articles/edu...
October 13, 2025 at 12:08 PM
@marcbonten.bsky.social has dedicated his career to advancing #clinicalmicrobiology & combatting #antimicrobialresistance. In his new role as Vice-Dean Education at @umcutrecht.bsky.social
he continues to inspire the next generation of healthcare scientists & researchers: ecraid.eu/articles/edu...
he continues to inspire the next generation of healthcare scientists & researchers: ecraid.eu/articles/edu...
On 15-SEP, the annual #PNEUMO EU F2F meeting with Ecraid’s operational team and funder MSD took place.
It was a fruitful meeting held at MSD headquarters in Haarlem, with a very nice tour around their facility.
Thanks to Kelly Johnson & #MSD NL for the hospitality & for continuous collaboration!
It was a fruitful meeting held at MSD headquarters in Haarlem, with a very nice tour around their facility.
Thanks to Kelly Johnson & #MSD NL for the hospitality & for continuous collaboration!
September 24, 2025 at 7:43 AM
📩 In our latest newsletter you can read more about Ecraid’s September highlights including studies updates and other milestones!
👉🏽 Meet us in Amsterdam at the ERS Congress & World Vaccine Congress. Book a meeting with our team: [email protected]
📫 Stay informed, subscribe now: bit.ly/EcraidNewsSe...
👉🏽 Meet us in Amsterdam at the ERS Congress & World Vaccine Congress. Book a meeting with our team: [email protected]
📫 Stay informed, subscribe now: bit.ly/EcraidNewsSe...
September 15, 2025 at 9:40 AM
📩 In our latest newsletter you can read more about Ecraid’s September highlights including studies updates and other milestones!
👉🏽 Meet us in Amsterdam at the ERS Congress & World Vaccine Congress. Book a meeting with our team: [email protected]
📫 Stay informed, subscribe now: bit.ly/EcraidNewsSe...
👉🏽 Meet us in Amsterdam at the ERS Congress & World Vaccine Congress. Book a meeting with our team: [email protected]
📫 Stay informed, subscribe now: bit.ly/EcraidNewsSe...
Our Education Newsletter is out now! Packed with opportunities and inspiration for early-career researchers and beyond: upcoming postgraduate courses, new scientific papers, a webinar recording you may have missed, & more resources to boost your knowledge 👉 mailchi.mp/ecraid/ecrai...
July 23, 2025 at 12:23 PM
Our Education Newsletter is out now! Packed with opportunities and inspiration for early-career researchers and beyond: upcoming postgraduate courses, new scientific papers, a webinar recording you may have missed, & more resources to boost your knowledge 👉 mailchi.mp/ecraid/ecrai...
Don't miss this chance to attend this course featuring insightful lectures, interactive afternoon workshops and invaluable network opportunities with other researchers and experts from across Europe & beyond
👇
www.escmid.org/event-detail...
@escmid.bsky.social @umcutrecht.bsky.social
👇
www.escmid.org/event-detail...
@escmid.bsky.social @umcutrecht.bsky.social
July 14, 2025 at 9:55 AM
Don't miss this chance to attend this course featuring insightful lectures, interactive afternoon workshops and invaluable network opportunities with other researchers and experts from across Europe & beyond
👇
www.escmid.org/event-detail...
@escmid.bsky.social @umcutrecht.bsky.social
👇
www.escmid.org/event-detail...
@escmid.bsky.social @umcutrecht.bsky.social
We are looking for a visionary Chief Executive Officer to lead Ecraid into its new chapter. If you are a purpose-driven and people-centred leader with bold ideas, an entrepreneurial spirit and a pan-European mindset, we’re looking for you!
More info 👉 www.ecraid.eu/careers
More info 👉 www.ecraid.eu/careers
July 9, 2025 at 9:27 AM
We are looking for a visionary Chief Executive Officer to lead Ecraid into its new chapter. If you are a purpose-driven and people-centred leader with bold ideas, an entrepreneurial spirit and a pan-European mindset, we’re looking for you!
More info 👉 www.ecraid.eu/careers
More info 👉 www.ecraid.eu/careers
📩In our latest newsletter you can read more about our upcoming educational opportunities and get the latest updates on publications and study milestones.
👉🏽We're hiring a Chief Executive Officer! Are you interested? Read more in our newsletter.
📫Stay informed, subscribe now: bit.ly/07NewsEcraid
👉🏽We're hiring a Chief Executive Officer! Are you interested? Read more in our newsletter.
📫Stay informed, subscribe now: bit.ly/07NewsEcraid
July 8, 2025 at 12:53 PM
📩In our latest newsletter you can read more about our upcoming educational opportunities and get the latest updates on publications and study milestones.
👉🏽We're hiring a Chief Executive Officer! Are you interested? Read more in our newsletter.
📫Stay informed, subscribe now: bit.ly/07NewsEcraid
👉🏽We're hiring a Chief Executive Officer! Are you interested? Read more in our newsletter.
📫Stay informed, subscribe now: bit.ly/07NewsEcraid
What are ethical, administrative, regulatory and logistical hurdles for delivery of RCTs & can these be qualified? Hot off the presses, this article in @jamanetworkopen.com by [email protected], the REMAP-CAP investigators & the Ecraid operational team: jamanetwork.com/journals/jam...
July 7, 2025 at 9:33 AM
What are ethical, administrative, regulatory and logistical hurdles for delivery of RCTs & can these be qualified? Hot off the presses, this article in @jamanetworkopen.com by [email protected], the REMAP-CAP investigators & the Ecraid operational team: jamanetwork.com/journals/jam...
Very pleased to announce a new speaker at our 'Better Methods' course in Athens: Prof. Sotirios Tsiodras! The programme will be updated shortly to reflect his topic.
Registration remains open for this unique learning experience for early-career investigators: www.escmid.org/event-detail...
Registration remains open for this unique learning experience for early-career investigators: www.escmid.org/event-detail...
July 3, 2025 at 1:16 PM
Very pleased to announce a new speaker at our 'Better Methods' course in Athens: Prof. Sotirios Tsiodras! The programme will be updated shortly to reflect his topic.
Registration remains open for this unique learning experience for early-career investigators: www.escmid.org/event-detail...
Registration remains open for this unique learning experience for early-career investigators: www.escmid.org/event-detail...